[Edaily Reporter Kim Seung-kwon ] Innosys(056090)announced on the 3rd that it has launched Urudent FXⅠ, which enhances connectivity with various digital prosthetic systems to enable dental professionals to provide more efficient treatment.
UruDent FXⅠ is designed with self-tapping and aggressive thread structures to ensure excellent initial stability even in hard or relatively weak alveolar bone. This provides stable implantation and a superior fit, enabling predictable initial stability across a wide range of bone types.
Additionally, by incorporating a conical/internal connection and a platform-switching design, the implant enhances prosthetic stability and connection precision while ensuring long-term stability of soft tissues and surrounding bone. It offers high compatibility with various digital prosthetic systems, supporting more efficient production of digitally customized prostheses while maintaining existing clinical workflows.
For surface treatment, sandblasting and acid etching (SLA) methods were applied to create surface characteristics conducive to osteocyte attachment and osseointegration, with a design focused on early healing and stable clinical outcomes.
With this launch, CG MedTech plans to continuously expand the UruDent brand’s product portfolio and broaden its footprint in the field of “digital dentistry.” Digital dentistry refers to technologies that digitize the entire dental treatment process—from diagnosis to treatment planning and prosthesis fabrication—using artificial intelligence (AI), 3D scanners, digital imaging equipment, and CAD/CAM.
Yoo Hyun-seung, CEO of CG MedTech, stated, “In the era of digital dentistry, a key competitive advantage lies not only in superior implant performance but also in how seamlessly the implant integrates with digital prosthetic systems.” He added, “UruDent FXⅠ is a product that simultaneously delivers clinical stability and treatment efficiency based on its excellent initial stability, SLA surface treatment technology, and compatibility with digital prosthetics.”
As forecasts suggest that a large number of financial institutions will be included in the second phase of the public sector relocation to regional areas, attention is turning to the regions that will…
#HEM Pharma Inc., a company specializing in microbiome healthcare, is accelerating the establishment of a key production hub targeting advanced global markets, including the U.S., after raising substa…
My first thought upon seeing the results of the second evaluation of the “Dokpa-mo” (Proprietary AI Foundation Model) was, “Is this really right?”This is because Motif Technologies—which had ranked fi…